Young Hak Kim

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. doi request reprint Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 71:1445-51. 2013
  2. doi request reprint Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Clin Lung Cancer 13:385-90. 2012
  3. doi request reprint Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 70:271-6. 2012
  4. pmc Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST)
    Shiro Tanaka
    Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyoku, Kyoto 606 8507, Japan
    Trials 12:120. 2011
  5. pmc Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
    Shiro Fujita
    Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, Japan
    BMC Med Genet 11:167. 2010
  6. doi request reprint Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Respir Med 104:434-9. 2010
  7. ncbi request reprint Gefitinib for non-small cell lung cancer patients with liver cirrhosis
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Intern Med 48:1677-9. 2009
  8. doi request reprint A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 39:576-81. 2009
  9. doi request reprint Maintenance chemotherapy for non-small-cell lung cancer
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Treat Rev 37:505-10. 2011
  10. doi request reprint Second-line chemotherapy for small-cell lung cancer (SCLC)
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Treat Rev 37:143-50. 2011

Collaborators

Detail Information

Publications47

  1. doi request reprint Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 71:1445-51. 2013
    ..Subset analysis of a previous phase III study comparing pemetrexed with docetaxel in the second-line setting showed the superiority of pemetrexed in an elderly (≥70) population in both efficacy and toxicity...
  2. doi request reprint Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Clin Lung Cancer 13:385-90. 2012
    ..The activities of IGF are strictly regulated by a family of IGF binding proteins (IGFBP), especially IGFBP3, a major serum carrier protein for IGF...
  3. doi request reprint Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 70:271-6. 2012
    ....
  4. pmc Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST)
    Shiro Tanaka
    Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyoku, Kyoto 606 8507, Japan
    Trials 12:120. 2011
    ..We are conducting a single arm phase II trial which aims to evaluate the efficacy and safety of this regime as a second- or third-line chemotherapy...
  5. pmc Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
    Shiro Fujita
    Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, Japan
    BMC Med Genet 11:167. 2010
    ..The aim of this study was to evaluate the influence of polymorphisms in the eNOS gene on prognosis of patients with advanced stage non-small-cell lung cancer (NSCLC)...
  6. doi request reprint Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Respir Med 104:434-9. 2010
    ..In approximately the year 2000, the results of a number of important studies of non-small-cell lung cancer (NSCLC) were published...
  7. ncbi request reprint Gefitinib for non-small cell lung cancer patients with liver cirrhosis
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Intern Med 48:1677-9. 2009
    ..Although further studies are needed, a reduced dose of gefitinib might be feasible for patients with liver dysfunction...
  8. doi request reprint A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 39:576-81. 2009
    ....
  9. doi request reprint Maintenance chemotherapy for non-small-cell lung cancer
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Treat Rev 37:505-10. 2011
    ..In this review, we summarize the major clinical trials of maintenance chemotherapy in patients with NSCLC, and discuss its clinical validity and present future perspectives...
  10. doi request reprint Second-line chemotherapy for small-cell lung cancer (SCLC)
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Treat Rev 37:143-50. 2011
    ..Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC. Better understanding of the molecular mechanisms is clearly needed...
  11. doi request reprint Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
    Shuji Ota
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Lung Cancer 64:98-104. 2009
    ....
  12. doi request reprint Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Oncol 5:950-5. 2010
    ..We investigated CSF concentrations of erlotinib and its active metabolite OSI-420...
  13. doi request reprint Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer
    Masahide Fukudo
    Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Sakyo ku, Kyoto, 606 8507, Japan
    Clin Pharmacokinet 52:593-609. 2013
    ..The secondary objective was to identify genetic determinant(s) for the cerebrospinal fluid (CSF) permeability of erlotinib and its active metabolite OSI-420...
  14. doi request reprint Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507 Japan
    Oncol Rep 26:795-803. 2011
    ..We also demonstrated that both IGF1-positive serum and wild-type EGFR were independent poor prognostic factors in patients with non-squamous NSCLC who received gefitinib therapy...
  15. doi request reprint Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan
    Clin Lung Cancer 12:307-12. 2011
    ..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in non-small-cell lung cancer (NSCLC) of malignant pleural effusion (MPE)...
  16. doi request reprint Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Lung Cancer 12:56-61. 2011
    ....
  17. doi request reprint Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto, 606 8507, Japan
    Med Oncol 29:3169-75. 2012
    ..As a consequence, evaluation using a combination of smoking status and vascular-poor area allows us to predict presence of EGFR mutations at a high frequency...
  18. doi request reprint Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Japan
    Cancer Chemother Pharmacol 70:399-405. 2012
    ..However, there has been no study in which cerebrospinal fluid (CSF) concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them...
  19. ncbi request reprint Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs
    Seiji Niho
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6 5 1, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:269-73. 2006
    ..Pretreatment computerized tomography (CT) films of the chest was studied to clarify the influence of interstitial shadow on developing interstitial lung disease (ILD)...
  20. doi request reprint Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 67:325-30. 2011
    ....
  21. doi request reprint Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer
    Young Hak Kim
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Lung Cancer 65:105-11. 2009
    ....
  22. doi request reprint Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncol Rep 25:377-82. 2011
    ....
  23. doi request reprint Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncology 84:214-8. 2013
    ..This study aimed to evaluate the association between BCL2 single-nucleotide polymorphisms and survival outcome in advanced non-small cell lung cancer (NSCLC)...
  24. doi request reprint Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Oncology 79:355-62. 2010
    ....
  25. doi request reprint Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Lung Cancer 74:98-102. 2011
    ..In contrast, the approved daily dose of gefitinib (250 mg) is only one-third of its MTD. Significantly different adverse events have been associated with gefitinib and erlotinib...
  26. doi request reprint Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 28:351-6. 2011
    ..The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future...
  27. doi request reprint Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Cancer 113:2518-23. 2008
    ..To the authors' knowledge, the prognostic factors in recurrent small cell lung cancer (SCLC) patients treated with second-line chemotherapy have not yet been clearly identified to date...
  28. doi request reprint Re-challenge chemotherapy for relapsed non-small-cell lung cancer
    Tatsuya Nagano
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Lung Cancer 69:315-8. 2010
    ..0 months and the 1-year survival rate was 60%. RC led to a significantly better overall survival rate than DOC (p=0.0342). RC could be an active second-line regimen in patients with relapsed NSCLC who responded to first-line chemotherapy...
  29. doi request reprint Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 29:1614-21. 2012
    ..We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR...
  30. doi request reprint Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Oncol 5:601-5. 2010
    ..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in such patients with nonsmall cell lung cancer (NSCLC)...
  31. pmc Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
    Cancer Chemother Pharmacol 68:1089-92. 2011
    ..We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib...
  32. doi request reprint Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer 117:819-25. 2011
    ....
  33. doi request reprint Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Lung Cancer 77:464-8. 2012
    ..Many patients received corticosteroids during retreatment, but not the one with recurrence of ILD. This may suggest that corticosteroids can prevent recurrence due to their antiinflammatory properties...
  34. doi request reprint Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Jpn J Clin Oncol 41:582-5. 2011
    ....
  35. doi request reprint Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Lung Cancer 13:304-11. 2012
    ..However, pneumonitis associated with chemotherapy was significantly increased in patients with preexisting ILD, and preexisting ILD is an independent prognostic factor for poorer survival...
  36. doi request reprint Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer
    Yuichi Sakamori
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer Sci 103:1065-70. 2012
    ..The correlation with clinical response to chemotherapy provides further support for the biologic relevance of these cells in patients' prognosis and highlights the potential use of CEPs as therapeutic targets...
  37. doi request reprint Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer
    Fengshi Chen
    Department of Thoracic Surgery, Kyoto University, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, 606 8507, Japan
    World J Surg 36:2858-64. 2012
    ..The purpose of the present study was to improve the prognosis of patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed induction chemoradiotherapy followed by surgery...
  38. doi request reprint Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo
    Hiroki Nagai
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606 8507, Japan
    Int J Oncol 41:24-30. 2012
    ..These findings suggest that NO donors, such as NOC-18 and GTN, enhance the anticancer effects of PEM by increasing the RFC1 and FPGS expression and stimulating cGMP signaling pathways in cancer cells...
  39. doi request reprint Two cases of cancer-associated retinopathy combined with small-cell lung cancer
    Yuichi Sakamori
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Jpn J Clin Oncol 41:669-73. 2011
    ..When cancer-associated retinopathy is suspected, a comparatively large quantity of steroids and anticancer treatment should be combined immediately...
  40. doi request reprint Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients
    Katsuhiro Masago
    Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Int J Clin Oncol 13:442-6. 2008
    ....
  41. doi request reprint Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
    Int J Clin Oncol 16:444-6. 2011
    ..In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab...
  42. ncbi request reprint Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
    Tohoku J Exp Med 222:51-3. 2010
    ..After discharge, the patient has received octreotide treatment for 6 months without serious adverse events. We suggest octreotide as a treatment option for FM...
  43. ncbi request reprint Predictive factors for local recurrence of resected colorectal lung metastases
    Satoshi Shiono
    Pathology Division, National Cancer Center Research Institute East, Chiba, Japan
    Ann Thorac Surg 80:1040-5. 2005
    ..However, local recurrence at the surgical margin is a problem with limited resections. This study attempted to identify predictive factors associated with local recurrences at the surgical margin after resection of pulmonary metastases...
  44. ncbi request reprint Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung
    Young Hak Kim
    Pathology Division, National Cancer Center Research Institute East, Chiba, Japan
    Clin Cancer Res 10:7311-7. 2004
    ..The aim of this study was to identify the clinicopathological and immunohistochemical features that are favorable to the use of gefitinib in adenocarcinoma patients...
  45. ncbi request reprint [A resected case of sclerosing thymoma]
    Young Hak Kim
    Division of Thoracic Oncology, National Cancer Center Hospital East
    Nihon Kokyuki Gakkai Zasshi 44:420-3. 2006
    ..Sclerosing thymoma should be taken into account, when only fibrous tissues are obtained by biopsy in patients with anterior mediastinal tumors...
  46. pmc Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Case Rep Oncol 4:470-4. 2011
    ..We believe that continuing EGFR-TKI treatment after disease progression should be an option in patients who previously responded to EGFR-TKI under the present circumstances...
  47. doi request reprint Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study
    Hiroki Nagai
    Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto, 606 8507, Japan
    Support Care Cancer 21:3271-8. 2013
    ..This study was conducted to determine whether dissolution with 5 % glucose solution would relieve vascular pain compared with the approved use of saline as the diluent...